Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 11/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 3/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407833 | 0.91 | ESR1 (0.40) | ESR1ESR2CYP2C19EPHX2RBP4 | |
| SCHEMBL5769208 | 0.84 | CHRNB2 (0.41) | ESR1ESR2PROKR1CYP2C19RBP4 | |
| SCHEMBL5769218 | 0.83 | ESR1 (0.40) | ESR1ESR2PROKR1 | |
| SCHEMBL5768898 | 0.83 | PROKR1 (0.46) | ESR1ESR2PROKR1 | |
| SCHEMBL2060704 | 0.83 | ESR1 (0.40) | ESR1ESR2PROKR1CYP2C19EPHX2 | |
| SCHEMBL5770265 | 0.82 | RBP4 (0.47) | ESR1ESR2PROKR1CYP2C19EPHX2 | |
| SCHEMBL5767104 | 0.81 | CHRNA1 (0.49) | ESR1ESR2PROKR1CYP2C19RBP4 | |
| SCHEMBL6395748 | 0.79 | ESR1 (0.37) | ESR1ESR2PROKR1CYP2C19RBP4 | |
| SCHEMBL2062184 | 0.79 | CHRNB4 (0.47) | ESR1ESR2 | |
| SCHEMBL6390039 | 0.78 | CHRNB2 (0.52) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020616-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020616-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | ESR1 1594/4885ESR2 1154/4885PROKR1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.